Paradigm has results from its Phase 2 hay fever trial pending in six weeks.
ACCESS THE FULL PRESENTATION HERE
View full PAR profile View Profile
Dr James Garner talked clinical-stage programs with investors.
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”